Gifthealth Delivers Off-The-Shelf Solution to Deliver MFN Pricing

Why It Matters

Rapid, MFN‑compliant DTP programs lower cost barriers and improve medication adherence, giving manufacturers a scalable way to demonstrate value and retain market share in a price‑sensitive environment.

Key Takeaways

• Gifthealth powers 90% of U.S. DTP volume.
• Programs launch in as few as 21 days.
• Supports 35,000 patients daily with 91% satisfaction.
• Cuts prescription abandonment by 50% versus national average.
• Integrates with all major EHRs, hubs, and CRMs.

Pulse Analysis

The rise of most‑favored‑nation (MFN) pricing has forced pharmaceutical manufacturers to prove every dollar spent delivers tangible outcomes. Direct‑to‑patient (DTP) channels, which bypass traditional pharmacy intermediaries, have become a critical lever for achieving price transparency and patient affordability. By embedding MFN pricing into a digital‑first DTP model, companies can align cost structures with real‑world utilization, a shift that resonates with payers demanding outcome‑based contracts and patients seeking lower out‑of‑pocket expenses.

Gifthealth’s new off‑the‑shelf solution capitalizes on this market pressure by offering a plug‑and‑play platform that can be operational in just 21 days. Its ability to integrate seamlessly with leading electronic health record (EHR) systems, specialty hubs, and customer relationship management (CRM) tools eliminates the typical IT bottlenecks that slow program launches. The platform automates electronic benefit investigations (eBI) and electronic benefit verifications (eBV), streamlining financial navigation and reducing administrative overhead. With a daily active base of more than 35,000 patients and a 91% satisfaction score, Gifthealth demonstrates that high‑volume, low‑cost drugs—some priced as low as $35—can be delivered efficiently at scale.

For manufacturers, the implications are twofold: faster time‑to‑market for MFN‑priced therapies and richer data insights into patient adherence and outcomes. The 50% reduction in prescription abandonment relative to the national average suggests that removing cost friction directly improves therapy persistence, a key metric in value‑based contracts. As the industry continues to prioritize cost containment and patient‑centric care, platforms like Gifthealth are poised to become indispensable partners in the evolving pharmaceutical supply chain.